vs

Side-by-side financial comparison of Clorox (CLX) and Labcorp (LH). Click either name above to swap in a different company.

Clorox is the larger business by last-quarter revenue ($4.8B vs $3.5B, roughly 1.3× Labcorp). On growth, Labcorp posted the faster year-over-year revenue change (5.8% vs -6.7%). Clorox produced more free cash flow last quarter ($637.0M vs $70.5M). Over the past eight quarters, Clorox's revenue compounded faster (62.2% CAGR vs 4.8%).

The Clorox Company is an American multinational manufacturer and marketer of consumer and professional products. Clorox ranked annually on the Fortune 500 list from 2000 to 2024, where it last held the #485 spot.

Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.

CLX vs LH — Head-to-Head

Bigger by revenue
CLX
CLX
1.3× larger
CLX
$4.8B
$3.5B
LH
Growing faster (revenue YoY)
LH
LH
+12.5% gap
LH
5.8%
-6.7%
CLX
More free cash flow
CLX
CLX
$566.5M more FCF
CLX
$637.0M
$70.5M
LH
Faster 2-yr revenue CAGR
CLX
CLX
Annualised
CLX
62.2%
4.8%
LH

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
CLX
CLX
LH
LH
Revenue
$4.8B
$3.5B
Net Profit
$277.8M
Gross Margin
28.7%
Operating Margin
10.8%
Net Margin
7.9%
Revenue YoY
-6.7%
5.8%
Net Profit YoY
30.5%
EPS (diluted)
$3.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLX
CLX
LH
LH
Q1 26
$4.8B
$3.5B
Q4 25
$1.7B
$3.5B
Q3 25
$3.6B
Q2 25
$2.0B
$3.5B
Q1 25
$1.7B
$3.3B
Q4 24
$1.7B
$3.3B
Q3 24
$1.8B
$3.3B
Q2 24
$1.9B
$3.2B
Net Profit
CLX
CLX
LH
LH
Q1 26
$277.8M
Q4 25
$157.0M
$164.7M
Q3 25
$261.1M
Q2 25
$332.0M
$237.9M
Q1 25
$186.0M
$212.8M
Q4 24
$193.0M
$143.4M
Q3 24
$99.0M
$169.3M
Q2 24
$216.0M
$205.3M
Gross Margin
CLX
CLX
LH
LH
Q1 26
28.7%
Q4 25
43.2%
28.2%
Q3 25
28.8%
Q2 25
46.5%
29.7%
Q1 25
44.6%
28.3%
Q4 24
43.8%
26.9%
Q3 24
45.8%
27.6%
Q2 24
46.5%
28.8%
Operating Margin
CLX
CLX
LH
LH
Q1 26
10.8%
Q4 25
7.6%
Q3 25
11.1%
Q2 25
20.6%
11.2%
Q1 25
15.2%
9.7%
Q4 24
14.1%
6.5%
Q3 24
10.0%
7.7%
Q2 24
14.5%
9.2%
Net Margin
CLX
CLX
LH
LH
Q1 26
7.9%
Q4 25
9.4%
4.7%
Q3 25
7.3%
Q2 25
16.7%
6.7%
Q1 25
11.2%
6.4%
Q4 24
11.4%
4.3%
Q3 24
5.6%
5.2%
Q2 24
11.4%
6.4%
EPS (diluted)
CLX
CLX
LH
LH
Q1 26
$3.35
Q4 25
$1.29
$1.98
Q3 25
$3.12
Q2 25
$2.68
$2.84
Q1 25
$1.50
$2.52
Q4 24
$1.54
$1.72
Q3 24
$0.80
$2.00
Q2 24
$1.74
$2.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLX
CLX
LH
LH
Cash + ST InvestmentsLiquidity on hand
$981.1M
Total DebtLower is stronger
$5.8B
Stockholders' EquityBook value
$8.7B
Total Assets
$19.1B
Debt / EquityLower = less leverage
0.67×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLX
CLX
LH
LH
Q1 26
$981.1M
Q4 25
$227.0M
$532.3M
Q3 25
$598.1M
Q2 25
$167.0M
$647.3M
Q1 25
$226.0M
$369.4M
Q4 24
$290.0M
$1.5B
Q3 24
$278.0M
$1.5B
Q2 24
$202.0M
$265.1M
Total Debt
CLX
CLX
LH
LH
Q1 26
$5.8B
Q4 25
Q3 25
Q2 25
$2.5B
Q1 25
Q4 24
Q3 24
Q2 24
$2.5B
Stockholders' Equity
CLX
CLX
LH
LH
Q1 26
$8.7B
Q4 25
$-125.0M
$8.6B
Q3 25
$8.7B
Q2 25
$321.0M
$8.5B
Q1 25
$27.0M
$8.3B
Q4 24
$-41.0M
$8.1B
Q3 24
$60.0M
$8.2B
Q2 24
$328.0M
$8.0B
Total Assets
CLX
CLX
LH
LH
Q1 26
$19.1B
Q4 25
$5.6B
$18.4B
Q3 25
$18.3B
Q2 25
$5.6B
$18.1B
Q1 25
$5.5B
$17.6B
Q4 24
$5.6B
$18.4B
Q3 24
$5.5B
$18.6B
Q2 24
$5.8B
$16.7B
Debt / Equity
CLX
CLX
LH
LH
Q1 26
0.67×
Q4 25
Q3 25
Q2 25
7.74×
Q1 25
Q4 24
Q3 24
Q2 24
7.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLX
CLX
LH
LH
Operating Cash FlowLast quarter
$191.5M
Free Cash FlowOCF − Capex
$637.0M
$70.5M
FCF MarginFCF / Revenue
13.3%
2.0%
Capex IntensityCapex / Revenue
2.5%
3.4%
Cash ConversionOCF / Net Profit
0.69×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLX
CLX
LH
LH
Q1 26
$191.5M
Q4 25
$614.2M
Q3 25
$387.2M
Q2 25
$294.0M
$620.6M
Q1 25
$286.0M
$18.5M
Q4 24
$180.0M
$777.2M
Q3 24
$221.0M
$277.3M
Q2 24
$340.0M
$561.1M
Free Cash Flow
CLX
CLX
LH
LH
Q1 26
$637.0M
$70.5M
Q4 25
$490.3M
Q3 25
$280.5M
Q2 25
$219.0M
$542.7M
Q1 25
$233.0M
$-107.5M
Q4 24
$127.0M
$665.1M
Q3 24
$182.0M
$161.5M
Q2 24
$259.0M
$432.9M
FCF Margin
CLX
CLX
LH
LH
Q1 26
13.3%
2.0%
Q4 25
13.9%
Q3 25
7.9%
Q2 25
11.0%
15.4%
Q1 25
14.0%
-3.2%
Q4 24
7.5%
20.0%
Q3 24
10.3%
4.9%
Q2 24
13.6%
13.4%
Capex Intensity
CLX
CLX
LH
LH
Q1 26
2.5%
3.4%
Q4 25
3.5%
Q3 25
3.0%
Q2 25
3.8%
2.2%
Q1 25
3.2%
3.8%
Q4 24
3.1%
3.4%
Q3 24
2.2%
3.5%
Q2 24
4.3%
4.0%
Cash Conversion
CLX
CLX
LH
LH
Q1 26
0.69×
Q4 25
3.73×
Q3 25
1.48×
Q2 25
0.89×
2.61×
Q1 25
1.54×
0.09×
Q4 24
0.93×
5.42×
Q3 24
2.23×
1.64×
Q2 24
1.57×
2.73×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLX
CLX

Segment breakdown not available.

LH
LH

Revenues$2.8B78%
Other$775.5M22%

Related Comparisons